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Abstract
Many people living with HIV (PLWH) pass through correctional facilities each year, a large proportion of whom do not 
maintain viral suppression following release. We examined the effects of imPACT, an intervention designed to promote post-
release viral suppression, on antiretroviral therapy (ART) adherence. PLWH awaiting release from prisons in two southern 
states were randomized to imPACT (consisting of motivational interviewing, care linkage coordination, and text message 
medication reminders) versus standard care (SC). ART adherence, measured by unannounced monthly telephone pill counts, 
was compared between study arms over 6 months post-release. Of 381 participants eligible for post-release follow-up, 302 
(79%) completed ≥ 1 of 6 possible pill counts (median: 4; IQR 1–6). Average adherence over follow-up was 80.3% (95% CI 
77.5, 83.1) and 81.0% (78.3, 83.6) of expected doses taken in the imPACT and SC arms, respectively. There was no differ-
ence between arms when accounting for missing data using multiple imputation (mean difference = − 0.2 percentage points 
[− 3.7, 3.3]), controlling for study site and week of follow-up. Of the 936 (40.9%) pill counts that were missed, 212 (22.7%) 
were due to re-incarceration. Those who missed pill counts for any reason were more likely to be unsuppressed, suggesting 
that they had lower adherence. However, missingness was balanced between arms. Among PLWH released from prison, ART 
adherence averaged > 80% in both study arms over 6 months—a level higher than seen with most other chronic diseases. 
However, missing data may have led to an overestimate of adherence. Factors independent of the intervention influence ART 
adherence in this population and should be identified to inform future targeted interventions.
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Introduction
Among people living with HIV (PLWH), antiretroviral 
therapy (ART) improves health outcomes including viral 
suppression, which directly translates to reduced rates of 
secondary transmission [1–3]. The potential of ART to 
reduce HIV transmission depends on early ART initiation 
and good adherence to treatment regimens once initiated 
[1, 2, 4]. ‘Seek, Test, Treat, and Retain’ (STTR) is an HIV 
intervention approach comprising early diagnosis, linkage 
to care, ART initiation, and retention in care that has the 
potential to substantially impact the HIV epidemic if uptake 
is high [5, 6].
The United States (US) correctional system is a unique 
setting where STTR has a particularly high potential to 
greatly improve health outcomes and reduce HIV transmis-
sion [7–11]. The prevalence of HIV in US prisons is sub-
stantially higher than in the general population [8, 12], and 
14–17% of PLWH in the US pass through the correctional 
system each year [13, 14]. Prisons typically conduct routine 
HIV testing to identify persons with undiagnosed HIV infec-
tion, and provide free access to care and ART throughout 
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the duration of incarceration [15]. Although estimates vary 
regarding the number of previously undiagnosed PLWH 
entering the correctional system [7, 12, 14–17], HIV care 
is initiated or re-initiated for many PLWH in this setting 
[15]. Consequently, an estimated 50–70% of PLWH have 
undetectable viral loads at the time of release from prison 
[9, 15, 18, 19].
For those individuals who do achieve viral suppression 
in prison, challenges during the transition back to the com-
munity post-release may have salient implications. Upon 
re-entry into the community, PLWH frequently are not 
linked successfully to sustained HIV care [20, 21]. Although 
PLWH are usually provided with short-term supplies of 
ART upon release from prison [13], many do not fill initial 
ART prescriptions after re-entry into the community [18], 
and individuals with a history of incarceration tend to have 
low adherence to prescribed ART regimens when out of 
prison [15, 22, 23]. These interruptions in ART mean that 
PLWH released from prison often do not maintain viral sup-
pression after re-entry into the community [15, 19, 24–26], 
putting these individuals at risk for HIV transmission to their 
partners [4].
Structural factors influence the ability of individuals 
released from prison to connect with community HIV care, 
maintain ART adherence, and avoid additional contacts with 
the correctional system. These factors include high preva-
lence of untreated mental illness and substance use, unstable 
housing, transportation issues, and lapses in employment 
and health insurance coverage, as well as the compounded 
stigma associated with having both HIV infection and a his-
tory of incarceration [13, 27–32]. Rates of re-incarceration 
are high, especially among PLWH [19, 24, 25, 27]. Studies 
have shown that individuals with multiple periods of incar-
ceration have worse HIV-related health outcomes, including 
viral non-suppression [24].
The imPACT (individuals motivated to Participate in 
Adherence, Care and Treatment) trial was among the first 
randomized trials of an intervention aiming to maintain viral 
suppression using the STTR approach in PLWH released 
from prison. The imPACT intervention was designed to 
specifically address multiple factors previously shown to be 
barriers to linkage to HIV care, retention in care, and ART 
adherence [33]. This multi-component, evidence-based trial 
was conducted in two large southern states, which combined 
have approximately one in seven of all individuals incarcer-
ated in the US. Previously published results found that viral 
suppression did not differ between study arms, indicating 
no significant effect of the intervention on viral suppression 
following prison release, but that viral suppression declined 
over time [20]. Given these findings, the present study aims 
to examine differences in ART adherence between study 
arms and provide an overall assessment of adherence to ART 
after release from prison.
Methods
Study Participants
PLWH incarcerated within the Texas (TX) Department of 
Criminal Justice or North Carolina (NC) Department of 
Public Safety who were English-speaking, at least 18 years 
of age, treated with ART, virally suppressed (defined as 
a recorded plasma HIV RNA level of < 400 copies/mL) 
within 90 days prior to release, and willing and able to 
provide written consent were eligible for enrollment into 
the imPACT trial. Participants were required to (a) have 
had an expected prison release date within approximately 
12 weeks after enrollment, and (b) not have been convicted 
of violent offenses (i.e., related to sexual assault, serious 
injury, or death) in order to minimize risk to study staff. 
Study screening and recruitment occurred during routine 
visits at prison medical clinics or in a private, secured 
room within the prison unit. Screening and enrollment 
have been described in detail previously [20]. Enrollment 
began in March 2012 and all study procedures were com-
pleted by February 2015.
Ethical Review
Trial procedures were approved by the institutional review 
boards (IRB) at Texas Christian University (TCU) and 
the University of North Carolina at Chapel Hill (UNC), 
as well as by human subjects committees at both prison 
systems and the US Office of Human Research Programs 
(OHRP). Approval for the analysis presented here was pro-
vided by the IRBs at TCU and UNC.
Study Design
The design of the imPACT trial has been described in 
detail previously [20, 33]. Eligible participants were ran-
domized 1:1 to the imPACT intervention arm or stand-
ard care (SC), with randomization stratified by state. All 
participants received discharge planning prior to release, 
which included referrals to community clinics, housing 
arrangements, and a supply of ART as per SC—a 10-day 
supply in TX and 30-day supply in NC. All study partici-
pants were provided with a cell phone for unannounced 
ART pill counts and reminders for study follow-up visits. 
The main elements of the intervention included (1) two 
in-prison sessions of motivational interviewing with cog-
nitive mapping and accompanying videos followed by an 
additional six sessions conducted by cell phone over the 
course of 12 weeks post-release, (2) a pre-release needs 
assessment with a study Link Coordinator, who then 
scheduled a community clinic appointment for the par-
ticipant within 5 days of release, and (3) cell phone text 
message reminders before each dose of ART for 12 weeks 
post-release.
Measures
The primary outcome of the present analysis was adher-
ence to ART, measured using telephone pill counts over 
6 months. Study staff conducted monthly unannounced 
cell-phone-based pill counts, which have been shown to be 
a valid, objective measure of ART adherence [34–36]. A 
baseline telephone pill count was conducted shortly after 
release to account for all medications. During each unan-
nounced monthly pill count, participants were asked to 
count and report how many pills they had remaining in their 
monthly pill bottle and how many pills had been dispensed 
to them since the last call. The expected number of pills a 
participant should have had remaining that month was deter-
mined using prescription label data, including number of 
pills dispensed, as reported over the phone by the participant 
reading the label. The observed number of pills taken since 
the prior count was calculated as the number of counted 
pills subtracted from the number of pills at the prior count, 
adjusting for pills dispensed and any other gains and losses. 
Similarly, the expected number of pills taken since the prior 
count was calculated based on the number of intervening 
days and the prescribed number of pills to be taken per day. 
Adherence was calculated as a ratio of the observed pills 
taken to expected pills taken, resulting in a continuous pro-
portion ranging from 0 to 1. At each monthly follow-up, 
study participants were classified as having a completed 
contact (a pill count was completed), re-incarcerated prior 
to the pill count, lost to follow-up, deceased, or a missed 
contact. A participant was classified as having a missed con-
tact if there was not a pill count completed for the particular 
month of follow-up, but they were not lost to follow-up at 
that time (i.e., they had later pill counts or other study visits) 
or re-incarcerated.
Viral suppression, the primary outcome of the trial, was 
defined as a plasma HIV-1 RNA level < 50 copies/mL, meas-
ured post-release at weeks 2, 6, 14, and 24. Demographic 
information was collected at baseline. Psychological func-
tioning and mental health status were collected at baseline 
using the modified TCU PSY Form and TCU HLTH Form, 
both of which have demonstrated high reliability and validity 
in this population [37, 38]. Prior alcohol use at baseline was 
measured using the Alcohol Use Disorders Identification Test 
(AUDIT) [39, 40] and prior drug use at baseline was meas-
ured using the TCU DSII Form [37, 41] in TX and Substance 
Abuse Subtle Screening Inventory (SASSI) [42] in NC. If an 
individual was re-incarcerated during follow-up, they 
were 
considered to be lost and no additional follow-up data was 
collected, including viral loads.
Analysis
We first conducted a complete-case intent-to-treat (ITT) anal-
ysis of post-release adherence to ART between arms using 
ordinary least squares regression with clustered standard errors 
for repeated observations per person, controlling for site and 
time since release. We also considered interactions by study 
site and time, examining Wald p-values for interaction terms 
(p < 0.1) and comparing stratified estimates and their 95% 
confidence intervals (CI). To account for nontrivial missing 
data, we then analyzed adherence over time between arms 
using multiple imputation with chained equations to impute 
adherence 50 times (Stata imputation code provided in Sup-
plementary Material 1). Data were assumed to be missing at 
random for the imputation model. Predictors of missing pill 
counts that were used in the imputation model were deter-
mined using area under the receiver operating curve. The 
variables included in the imputation model were (in order 
of addition) social support (modeled as quadratic), week of 
follow-up, site, incarceration length, education, psychological 
distress, age, intervention, intimate partner violence, race and 
ethnicity, and sex. Other imputation models were run, varying 
the order of variable addition, but the order of the variables 
in the imputation model had a negligible effect on the model 
estimates. The largest Fraction of Missing Information (FMI) 
in the adjusted regression model using imputed data was 36% 
(FMI by model parameter shown in Supplementary Mate-
rial 2). Re-incarceration and death were treated as compet-
ing risks, i.e., adherence measures were not imputed for time 
points after these events. Social support was missing for < 1% 
of observations, so was included as an imputed variable. All 
other variables had complete data for participants who did not 
experience competing risks.
We assessed adherence, pill count completion, and re-
incarceration stratified by participant characteristics. Finally, 
to evaluate adherence in relation to viral suppression, we 
assessed pill count completion and viral suppression among 
participants with viral load (VL) laboratory measures at 
month 6 of follow-up.
Data management was completed in SAS version 9.4 
(Cary, NC) and all analyses were conducted using Stata 14 
(College Station, TX).
Results
Participant Characteristics
There were 1802 patients screened for the imPACT trial and 
of these, 1324 were ineligible and 73 declined to participate. 
A total of 405 participants were enrolled and randomized 
in TX (n = 242) and NC (n = 163). Of the 405 eligible par-
ticipants who were enrolled and randomized, 24 were with-
drawn following randomization because they became ineli-
gible, mostly due to an extension of their prison sentence or 
because they were newly recognized as a threat to safety of 
the study staff (11 from the imPACT arm and 13 from the 
SC arm). Among the remaining 381 participants, 195 were 
in the intervention arm and 186 participants in SC. Base-
line characteristics were balanced between arms (Table 1). 
Participants were mostly black men, never married, with a 
median age of 43–44 years, and incarcerated < 1 year.
ART Adherence by Study Arm
Seventy-nine percent of study participants (n = 302) com-
pleted at least 1 pill count (median: 4, IQR 1–6) over 
6 months of follow-up. Mean adherence (percentage of 
expected doses taken) across pill counts was 80.3% (95% 
CI 77.5, 83.1) in the imPACT arm and 81.0% (95% CI 
78.3, 83.6) in the SC arm. Figure 1 shows unadjusted com-
plete-case adherence over time in each study arm. Mean 
adherence at each of the 6 months of follow-up ranged 
from 78.5% to 84.0% in the imPACT arm and 76.6% 
to 84.8% in the SC arm. In the complete-case analysis 
controlling for site and week of follow-up (Table 2), adher-
ence did not differ between arms (mean difference = − 0.6 
percentage points; 95% CI − 4.4, 3.1). While overall adher-
ence differed by study site (data not shown), no significant 
interactions were observed between the intervention and 
site or week of follow-up.
Table 1  Baseline characteristics 
of study participants
a Missing data: CD4 (0.3%), substance use (4%)
Characteristic imPACT (n = 195) SC (n = 186)
n (%) or median (IQR) n (%) or median (IQR)
Age 44 (35–49) 43 (34–49)
Male sex 147 (79) 150 (77)
Race
 White 46 (24) 39 (21)
 Black 121 (62) 128 (69)
 Other 28 (14) 19 (10)
Hispanic ethnicity 10 (5) 17 (9)
CD4 cell count/mm3a 490 (339–709) 511 (300–734)
Incarceration length (years) 0.74 (0.47–1.75) 0.81 (0.48–1.85)
Psychological distress
 Not high 129 (66) 133 (72)
 High 22 (11) 24 (13)
 Very high 44 (23) 29 (16)
Education
 Some high school 76 (39) 80 (43)
 High school/GED 73 (37) 61 (33)
 Some college/trade school 46 (24) 45 (24)
Marital status
 Married 33 (17) 24 (13)
 Formerly married 47 (24) 35 (19)
 Never married 115 (59) 127 (68)
History of substance  usea 127 (68) 116 (66)
Fig. 1  Average ART adherence (95% CI) by study arm, using com-
plete cases
Loss to follow-up and missed contacts were common. 
Figure 2 shows follow-up status over time by study arm. 
Of all participants, 67% (n = 256) were retained in the trial 
for 6 months, but only 44% (n = 167) of study participants 
completed the final pill count at 6 months post-release 
(Fig. 2). During study follow-up, 17% of the sample were 
re-incarcerated. Missed pill counts were common; 40.9% 
(n = 936) of all pill counts were missed at some point dur-
ing follow-up. Of these, 22.7% (n = 212) were missed due 
to re-incarceration. Re-incarceration, loss to follow-up, 
and missed contacts were balanced between study arms. 
Participants who completed all follow-up contacts had 
consistently higher mean adherence throughout follow-up 
than participants who were missed, lost, or re-incarcer-
ated (data not shown). Analysis of adherence over time 
between arms using multiple imputation to correct for 
missing data was consistent with the complete-case analy-
sis, showing comparable adherence between study arms 
(mean difference = -0.2 percentage points; 95% CI − 3.7, 
3.3), controlling for site and week of follow-up (Table 2).
ART Adherence, Study Follow‑up, and Participant 
Characteristics
Average adherence was similar across most covariates 
(Table 3), although adherence was lowest among participants 
Table 2  Intent-to-treat comparison of average adherence by arm by (a) complete-case analysis, and (b) multiple imputation (MI) to account for 
missing data, controlling for site and week of follow-up
a Adjusted for site and week of follow-up
b Missing data: 40.9% (n = 936) of all pill counts were missed. Missed counts due to re-incarceration or death (24.3% of missed counts) were 
treated as a competing risk and not imputed
% Mean adherence (95% CI)
Analysisa imPACT SC % Mean difference (95% CI)
A. Complete  caseb 81.9 (78.6, 85.1) 82.5 (78.8, 86.2) − 0.6% (− 4.4, 3.1)
B. Multiple imputation 81.0 (77.5, 84.5) 81.2 (77.4, 85.0) − 0.2% (− 3.7, 3.3)
Fig. 2  Follow-up status over 6 months by study arm
Table 3  Comparison of average adherence, completion of pill counts, 
and re-incarceration by key covariates, using complete cases
Average 
adherence 
(n = 381)
% Com-
pleted counts 
(n = 381)
% Re-
incarcerated 
(n = 63)
Age
 20–29 79.1 59.3 14.0
 30–39 81.1 48.7 18.8
 40–49 79.7 61.3 20.3
 50 + 82.2 67.0 9.0
Sex
 Male 80.8 59.9 16.2
 Female 80.1 56.0 17.9
Race
 White non-His-
panic
81.0 54.5 15.3
 Black non-His-
panic
80.4 61.3 16.1
 Other non-His-
panic
81.3 55.3 21.3
 Hispanic ethnicity 80.9 53.7 18.5
Incarceration length
 < 6 months 78.4 44.3 25.5
 7–12 months 80.7 56.1 17.8
> 1 year 81.5 71.7 9.3
Education
Some HS 81.7 53.6 23.7
HS Diploma/GED 77.6 59.0 13.4
Some college/trade 
school
83.0 68.5 8.8
Psychological 
distress
 Not high 79.8 63.8 10.1
 High distress 81.2 51.0 12.9
 Very high distress 77.6 40.8 22.8
with only a high school (HS) diploma or GED (77.6%) com-
pared to those with less than a HS diploma/GED or with 
some college (81.7% and 83.0%, respectively), and among 
those who screened positive for very high psychological 
distress (77.6%) compared to participants with lower levels 
or no signs of distress (81.2% and 79.8%). Adherence was 
also lower among those incarcerated < 6 months (78.4%) 
than among those incarcerated 7 to < 12 months (80.7%) 
or ≥ 12 months (81.5%). The percentage of completed pill 
counts was lowest among participants age 30–39 (48.7%), 
those with less than a HS diploma (53.6%), those incarcer-
ated < 6 months (44.3%), and those screening positive for 
very high psychological distress (40.8%). Participants of 
other than white or black race were most likely to be re-
incarcerated (21.3%), as were those incarcerated < 6 months 
(25.5%), with less than a HS diploma/GED (23.7%), or 
very high psychological distress (22.8%). Only psychologi-
cal distress and incarceration length were associated with 
all three outcomes (adherence, pill count completion, and 
re-incarceration).
Although ART adherence remained steady at approxi-
mately 80% throughout follow-up among those complet-
ing pill counts, our previously published report found that 
viral suppression prevalence steadily declined throughout 
follow-up [20]. Sixty percent and 61% of participants who 
completed follow-up in the imPACT (n = 128) and SC arms 
(n = 125) were virally suppressed at 24 weeks post-release, 
with no difference between arms [20]. ART adherence and 
VL were assessed on different schedules (final pill count 
in week 21, final VL in week 24) and had different pat-
terns of missingness (so long as participants were not re-
incarcerated, at which point both outcomes were censored). 
Therefore, we were able to assess whether viral suppression 
differed between those with and without missing pill counts 
prior to the final VL measure. Of all 253 participants with a 
week 24 VL, 114 (71.3%) of the 160 participants who also 
had a completed pill count at week 21 post-release remained 
virally suppressed at the end of study follow-up, compared 
to 41 (44.1%) of the 93 participants who did not complete 
the week 21 pill count but did have a week 24 VL (data not 
shown).
Discussion
In this randomized trial of a multi-component intervention 
aimed at maintaining viral suppression in PLWH released 
from prison, adherence to ART was relatively high, aver-
aging above 80%, and did not differ between the imPACT 
and standard care arms throughout follow-up. This result is 
consistent with the primary outcome of the imPACT trial, 
which found no difference in viral suppression between 
arms at 6 months following release from prison [20]. When 
accounting for nontrivial missing data using multiple impu-
tation, this finding of no difference between study arms 
held. Of note, while adherence did not differ between arms, 
adherence to long-term therapy in this study population was 
higher than has often been seen among patients with other 
chronic diseases [43–45]. Adherence was higher than seen in 
some analyses of individuals released from prison; [15, 22] 
however, it is not inconsistent with all studies of post-release 
interventions. Teixeira et al. [46] found sustained high levels 
of ART adherence among PLWH released from New York 
City Jails who received a transitional care-coordination plan 
upon release.
The imPACT intervention was an evidence-based inter-
vention designed to enhance motivation to enter commu-
nity-based HIV care and support linkage to care and ART 
adherence [33]. The design was based on extensive evidence 
of challenges that PLWH released from prison face upon re-
entry into the community, using a multi-component design 
to simultaneously address multiple factors that hinder care 
access and ART adherence among recently released PLWH. 
The similarity in adherence between study arms suggests 
that additional factors not adequately addressed by the inter-
vention influence ART adherence following prison release. 
Identifying and addressing additional factors that contrib-
ute to adherence, HIV care engagement, and attrition may 
further improve prison-to-community linkage to care, ART 
adherence, and rates of viral suppression following com-
munity re-entry.
Previous studies have found that psychological comorbid-
ity negatively impacts ART adherence among PLWH [47, 
48], including those with a history of incarceration [30]. This 
is consistent with our finding of lower-than-study-average 
adherence among individuals with high psychological dis-
tress. An analysis by Montague et al. [49] of linkage to care 
among PLWH released from correctional facilities found 
that individuals who had been incarcerated > 6 months had 
a shorter time to care linkage after release than those with 
a shorter period of incarceration. In that study, the authors 
hypothesized that during longer incarceration periods, indi-
viduals may receive education, more discharge planning, and 
medical stabilization that then may influence linkage to care 
upon release. Similarly, Baillargeon et al. [18]. found that 
individuals with longer duration of incarceration (≥ 1 year) 
were more likely to fill an ART prescription shortly after 
prison release than those who had been in prison < 1 year. In 
this study, individuals with longer duration of incarceration 
were more likely to have received help with their applica-
tions for drug assistance. The findings from these studies are 
consistent with our finding that adherence to ART was lower 
among individuals incarcerated < 6 months.
Previously published results from this trial show that 
despite consistently high adherence, participants in both 
study arms who completed follow-up VL testing experienced 
a steady loss of viral suppression in the 6 months following 
prison release [20]. This apparent inconsistency may be due 
in part to greater capture of VL data than pill count data in 
the full study population, along with the likelihood that those 
with missing pill count data were likely to have lower-than-
average adherence. Compared to participants without miss-
ing pill counts, those with missing counts exhibited lower 
adherence when they were still active in the study, suggest-
ing that our complete-case analysis overestimated adherence 
in the full study population. The complete-case analysis of 
VL data may have been less susceptible to overestimation, 
as viral non-suppression among at least some of those with 
missing pill count data was captured. We additionally note 
that the similarity of results between our complete-case and 
multiple imputation analyses of adherence suggests that 
observed factors alone may not be sufficient to accurately 
impute missing adherence values.
All study participants received a cell phone for study 
contact purposes and engaged in regular contact with study 
staff, including appointment reminders and unannounced 
monthly pill counts. Cell phone provision and regular con-
tact with study staff may have acted as an intervention in the 
SC arm by providing support and motivation to the study 
participants, and in this way may have helped these partici-
pants overcome some of the destabilizing effects of prison 
release and community re-entry in order to maintain good 
ART adherence. Prior research has shown that cell phones 
provided to women with substance use and depression may 
assist with linkage to services after release from prison [50]. 
The main findings from the imPACT trial also demonstrated 
that overall attendance at HIV care appointments was similar 
between arms [20], which may be partially explained by cell 
phone provision and regular contact by study staff in both 
study arms.
The number of individuals lost to study follow-up was 
high, but unsurprising based on other studies in similar pop-
ulations [21, 46]. Re-incarceration was the most common 
reason for loss to follow-up in this study population, with 
close to one-fifth of the study population re-incarcerated 
during follow-up, accounting for a large portion of missed 
pill counts. This level of re-incarceration is consistent with 
previous studies [22, 23, 25, 27], which have demonstrated 
that many individuals who come into contact with the US 
correctional system experience a “revolving door” effect, 
with frequent re-incarceration events [27, 51]. Similar to 
other studies among persons released from US prisons, re-
incarceration in this study was most common among less 
educated individuals [52] and those with evidence of psy-
chological distress [25, 53]. Individuals who did not com-
plete follow-up were also less adherent to ART before they 
were lost.
Several study limitations should be considered when 
interpreting the results of this analysis. First, as previously 
discussed, there was a large amount of missing data due to 
missed contacts, re-incarceration, and loss to follow-up, with 
two-fifths of pill counts missed. However, missing data was 
balanced between arms, and analyses using multiple impu-
tation to account for these missing data supported findings 
from the complete-case analysis of no difference between 
arms. Unmeasured factors are likely associated with miss-
ing adherence measures (i.e., non-ignorable missing data) 
and therefore the underlying assumption of data missing 
at random for our imputation model may not be met. This 
non-ignorable missingness potentially contributes to the 
inconsistent trial results of decline in viral suppression over 
follow-up despite consistently high ART adherence. Second, 
unannounced monthly pill counts, while a valid and reli-
able measure of adherence, may be an imperfect measure of 
ART adherence because counts cannot be visually confirmed 
[34–36]. Third, cell phone provision to both study arms may 
have affected medication adherence in the SC arm, and the 
monthly research study phone contacts for pill counts may 
have acted as an intervention in their own right. Finally, 
this analysis was conducted in only two state prison systems 
and the study population was mostly male. While these two 
states account for more than 1 in 7 members of the incarcer-
ated population in the US, the results of this analysis may 
not be generalizable to the larger US population of PLWH 
released from prison.
Conclusions
In conclusion, overall ART adherence in this population of 
PLWH newly released from prison was high, averaging over 
80% through 6 months following release. However, missing 
data may have led to an overestimate of adherence. There 
was no difference in ART adherence between the imPACT 
and SC arms even when accounting for missing data, indi-
cating that there are factors not adequately addressed by 
the intervention that influence ART adherence following 
release from prison in this population. Cell phone provision 
and monthly pill counts may have acted as an intervention 
in the SC arm and could partially explain our findings of 
no difference between study arms. Given high rates of re-
incarceration, a continued focus on creating a continuum of 
care between prison correctional facilities and community 
HIV care is crucial to address ART adherence and loss of 
viral suppression among PLWH re-entering the community 
after prison release.
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